What it's for (Indications)
- Eptacog alfa is a recombinant activated coagulation Factor VII (rFVIIa) indicated for the treatment of bleeding episodes and for the prevention of bleeding in surgical interventions or invasive procedures in patients with congenital hemophilia A or B with inhibitors to Factor VIII or Factor IX.
- It is also approved for patients with acquired hemophilia, congenital Factor VII deficiency, and Glanzmann's thrombasthenia with refractoriness to platelet transfusions, or when platelets are not available.
- This broad range of indications addresses significant hemostatic challenges where conventional clotting factor replacement therapies may be ineffective or unavailable, providing a critical therapeutic option for complex bleeding disorders.
- The drug acts by initiating the extrinsic coagulation pathway at the site of vascular injury, effectively promoting hemostasis.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of eptacog alfa is highly individualized and depends critically on the patient's weight, the severity and location of the bleeding episode, the type of surgical procedure, and the patient's clinical response. It is administered intravenously (IV) as a bolus injection. For hemophilia patients with inhibitors, a common starting dose for bleeding episodes is typically 90 mcg/kg, which may be repeated every 2 hours until hemostasis is achieved and maintained. For surgical prophylaxis, the dosing regimen is also tailored, often involving multiple doses. For other indications, specific dosing guidelines apply based on the patient's condition and the nature of the bleeding or procedure. Close clinical monitoring and appropriate laboratory assessments are essential to optimize treatment and minimize potential risks, ensuring both efficacy and safety. |
Safety & Warnings
Common Side Effects
- Commonly reported adverse reactions to eptacog alfa include fever, decreased therapeutic response, and various injection site reactions such as pain or inflammation.
- However, the most serious and clinically significant side effects are related to thromboembolic events, which can manifest as deep vein thrombosis, pulmonary embolism, myocardial infarction, or cerebrovascular accidents.
- These events, though rare, underscore the drug's potent procoagulant activity and the importance of careful patient selection and monitoring, particularly in individuals with pre-existing risk factors for thrombosis.
- Hypersensitivity reactions, including anaphylaxis, can also occur, necessitating immediate medical intervention.
- Other potential side effects include disseminated intravascular coagulation (DIC), abnormal laboratory values, and transient hypotension, requiring vigilant observation.
Serious Warnings
- Black Box Warning: **Serious Warnings** While eptacog alfa does not carry a formal FDA-mandated Black Box Warning, its use is associated with a significant risk of thromboembolic events, which warrants serious consideration. Healthcare professionals and patients must be acutely aware of the potential for serious arterial and venous thrombotic complications, including but not limited to deep vein thrombosis, pulmonary embolism, myocardial infarction, and cerebrovascular accidents (stroke). These events can be life-threatening or result in permanent disability. The risk is particularly elevated in patients with underlying conditions predisposing them to thrombosis, such as atherosclerosis, advanced age, or a history of thrombotic events. Close clinical monitoring for signs and symptoms of thrombosis is imperative throughout treatment. Concurrent use of antifibrinolytic agents (e.g., tranexamic acid, epsilon-aminocaproic acid) can further amplify this risk, requiring extreme caution and vigilant supervision. Patients should be educated on the symptoms of a blood clot and advised to seek immediate medical attention if such symptoms occur. This potent procoagulant agent, while life-saving for severe bleeding, must be used with judicious consideration of its thrombogenic potential.
- Patients receiving eptacog alfa should be closely monitored for signs and symptoms of thromboembolic events, including deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke, especially if they have pre-existing risk factors such as atherosclerosis, advanced age, or a history of thrombotic disease.
- Concurrent administration with antifibrinolytics (e.
- g.
- , tranexamic acid, epsilon-aminocaproic acid) should be approached with extreme caution due to the potential for increased thrombotic risk; if necessary, careful clinical and laboratory monitoring is warranted.
- Hypersensitivity reactions, including anaphylaxis, have been reported; patients should be advised of the potential for such reactions and seek immediate medical attention if symptoms occur.
- Eptacog alfa contains trace amounts of mouse and hamster protein, and bovine protein; patients with known hypersensitivity to these animal proteins should be carefully evaluated prior to administration.
How it Works (Mechanism of Action)
Eptacog alfa, a recombinant activated coagulation Factor VII (rFVIIa), exerts its therapeutic effect by directly activating Factor X to Factor Xa and, to a lesser extent, Factor IX to Factor IXa, without requiring Factor VIII or Factor IX as cofactors. This activation occurs primarily at the site of vascular injury, where tissue factor is exposed. The resulting Factor Xa then combines with Factor Va to form the prothrombinase complex, which rapidly converts prothrombin to thrombin. Thrombin, in turn, converts fibrinogen to fibrin, leading to the formation of a stable fibrin clot that effectively achieves hemostasis. This mechanism is particularly advantageous in patients with hemophilia A or B who have developed inhibitory antibodies against Factor VIII or Factor IX, as it bypasses the need for these deficient or inhibited factors, providing a direct procoagulant impulse to initiate clot formation.
Commercial Brands (Alternatives)
No other brands found for this formula.